{
  "docId": "019de517-75a1-7387-968b-d0dc513bf421",
  "docSlug": "e930bfcc8684afb6f5a4dd5442b5166d",
  "documentTitle": "Ocuphire Pharma | Investor Presentation Deck | 42 slides",
  "authorId": "ocuphire-pharma",
  "authorName": "Ocuphire Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 42,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 16,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-75a1-7387-968b-d0dc513bf421/35",
  "deckHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421",
  "deckJsonHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421.json",
  "deckAnchorHref": "/decks/019de517-75a1-7387-968b-d0dc513bf421#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.025,
        "w": 0.08,
        "x": 0.049,
        "y": 0.935
      },
      "kind": "image",
      "text": "Ocuphire Pharma logo",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd261264-db6b-4d5c-b0a4-73c16c26835f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.77,
        "x": 0.049,
        "y": 0.096
      },
      "kind": "paragraph",
      "text": "Comprehensive Body of Clinical Data Supporting Efficacy and Safety Across 3 Indications",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff5938b2-712d-49e8-828e-b76551b712ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.019,
        "x": 0.936,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "35",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "630192c5-7567-41a6-b901-2780069e71b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.73,
        "w": 0.901,
        "x": 0.049,
        "y": 0.188
      },
      "kind": "table",
      "text": "Indication & Status: Ryzumvi™ Approved September 2023, Presbyopia (POS Alone) Phase 3, Presbyopia (POS + LDP) Phase 3, DLD 2nd Phase 3\nPrimary Endpoint: Return to baseline pupil diameter at 90 minutes after dilation, ≥3 line gain in near vision with loss of no more than 1 line in distance vision, ≥3 lines (eye test) of improvement in mesopic low contrast best-corrected distance visual acuity (mLCVA)\nEfficacy Data: Met Phase 3 primary endpoint MIRA-3: 58% POS vs. 6% placebo MIRA-2: 49% POS vs. 7% placebo (p<0.0001) MIRA-4: 64% POS vs. 25% placebo; Met planned Phase 3 primary endpoint VEGA-1: 29% POS vs. 12% placebo at 12 hrs post-POS dose (p=0.02); Met Phase 2 primary endpoint Met planned Phase 3 primary endpoint VEGA-1: 61% combo post-LDP dose (30 min) + post-POS dose (12 hrs) vs. 14% placebo (p<0.0001); Met Phase 3 primary endpoint LYNX-1: 13% POS vs. 3% placebo at Day 8 (p<0.05) and 21% in POS vs.3% placebo at Day 15 (p<0.01)\nKey Secondary Endpoint(s): Efficacy across all mydriatic agents, iris color, 1 or 2 drops, and all ages (3-80); Durable near vision (18 hrs) Optimal pupil size Pupillary light reflex; Durable near vision gain Optimal pupil size Pupillary light reflex; Improvement visual acuity measures (distance and near) in dim light conditions\nSafety & Tolerability: No headaches, No blurry vision, ~5% mild redness, No change in IOP, No SAES, Most AEs were mild",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dc15142-22c9-43f7-bbd9-e2be57c58bf8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.719,
        "x": 0.049,
        "y": 0.06
      },
      "kind": "title",
      "text": "Summary of Phentolamine Ophthalmic Solution 0.75% Trial Results",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac23f629-7372-4a8f-8bd6-1c4aa7766c21",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "616159bd-d222-49fe-b9cb-c6b1ab092719",
      "evidence": "table/data: Indication & Status: Ryzumvi™ Approved September 2023, Presbyopia (POS Alone) Phase 3, Presbyopia (POS + LDP) Phase 3, DLD 2nd Phase 3",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 29,
      "beatId": "691510f1-c63c-46db-bda1-6d94434f6f9b",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 29-42 discuss key takeaways, corporate highlights, and future plans",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}